Mihaela Cristea

5.1k total citations · 1 hit paper
110 papers, 2.2k citations indexed

About

Mihaela Cristea is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mihaela Cristea has authored 110 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 35 papers in Reproductive Medicine and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mihaela Cristea's work include Ovarian cancer diagnosis and treatment (35 papers), PARP inhibition in cancer therapy (20 papers) and Lung Cancer Treatments and Mutations (12 papers). Mihaela Cristea is often cited by papers focused on Ovarian cancer diagnosis and treatment (35 papers), PARP inhibition in cancer therapy (20 papers) and Lung Cancer Treatments and Mutations (12 papers). Mihaela Cristea collaborates with scholars based in United States, Canada and Australia. Mihaela Cristea's co-authors include Marianna Koczywas, Ursula A. Matulonis, Karen L. Reckamp, Betty Ferrell, Tami Borneman, Gini F. Fleming, Virginia Sun, Amit M. Oza, Robert J. Morgan and Gwen Uman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Mihaela Cristea

105 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019 377 citations Mihaela Cristea, Ursula A. Matulonis et al. profile →

Peers

Mihaela Cristea

ONCOL

SURGE

PRM

Cor D. de Kroon Netherlands

Sarah M. Temkin United States

Karina Dahl Steffensen Denmark

Elisabeth Åvall‐Lundqvist Sweden

Christine Walsh United States

Violante Di Donato Italy

Innocenza Palaia Italy

Jubilee Brown United States

Paul R. Harnett Australia

Susan C. Modesitt United States

Cor D. de Kroon Netherlands

Mihaela Cristea

768 ×0.6

ONCOL

1.3k ×1.9

401 ×0.8

632 ×1.8

SURGE

363 ×1.2

PRM

Citations per year, relative to Mihaela Cristea Mihaela Cristea (= 1×) peers Cor D. de Kroon

Countries citing papers authored by Mihaela Cristea

Since Specialization

Citations

This map shows the geographic impact of Mihaela Cristea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihaela Cristea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihaela Cristea more than expected).

Fields of papers citing papers by Mihaela Cristea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihaela Cristea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihaela Cristea. The network helps show where Mihaela Cristea may publish in the future.

Co-authorship network of co-authors of Mihaela Cristea

This figure shows the co-authorship network connecting the top 25 collaborators of Mihaela Cristea. A scholar is included among the top collaborators of Mihaela Cristea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mihaela Cristea. Mihaela Cristea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adamson, A. W., Yuan Chun Ding, Linda Steele, et al.. (2023). Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer. Journal of Ovarian Research. 16(1). 141–141. 6 indexed citations

Reckamp, Karen L., Carolyn E. Behrendt, Thomas P. Slavin, et al.. (2021). Germline mutations and age at onset of lung adenocarcinoma. Cancer. 127(15). 2801–2806. 18 indexed citations

Raoof, Mustafa, Gautam Malhotra, Michael P. O’Leary, et al.. (2021). PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Annals of Surgical Oncology. 29(1). 175–185. 13 indexed citations

Cristea, Mihaela, Paul Frankel, Timothy W. Synold, et al.. (2020). 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort. Annals of Oncology. 31. S639–S639. 1 indexed citations

Borneman, Tami, Diane Cope, Huiyan Ma, et al.. (2020). A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study. European Journal of Oncology Nursing. 49. 101855–101855. 14 indexed citations

Akhavan, David, Paul J. Yazaki, Dave Yamauchi, et al.. (2020). Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 35(1). 10–15. 19 indexed citations

Cristea, Mihaela, Wenge Wang, Mark T. Wakabayashi, et al.. (2019). Highlights of the NCCN Oncology Research Program. Journal of the National Comprehensive Cancer Network. 17(1). xxxvii–xxxvii. 1 indexed citations

Cristea, Mihaela, Wenge Wang, Mark T. Wakabayashi, et al.. (2019). Oncology Research Program. Journal of the National Comprehensive Cancer Network. 17(9). xxvi–xxvi. 1 indexed citations

Cristea, Mihaela, Paul Frankel, Timothy W. Synold, et al.. (2019). A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemotherapy and Pharmacology. 83(3). 589–598. 25 indexed citations

10.

Luu, Thehang, Paul Frankel, Jan H. Beumer, et al.. (2019). Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemotherapy and Pharmacology. 84(6). 1201–1208. 11 indexed citations

11.

Pan, Kathy, et al.. (2019). Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Targeted Oncology. 14(3). 269–283. 6 indexed citations

12.

Hardwick, Nicola, Paul Frankel, Christopher Ruel, et al.. (2018). p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical Cancer Research. 24(6). 1315–1325. 54 indexed citations

13.

Liu, Stephen V., Susan Groshen, Karen Kelly, et al.. (2018). A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 82(4). 723–732. 5 indexed citations

14.

Murad, John P., Anna Kozłowska, Hee Jun Lee, et al.. (2018). Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Frontiers in Immunology. 9. 2268–2268. 100 indexed citations

15.

Esselen, Katharine M., Angel M. Cronin, Kristin Bixel, et al.. (2016). Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. Obstetrical & Gynecological Survey. 71(11). 660–661. 13 indexed citations

16.

Wright, Alexi A., Angel M. Cronin, Dana Milne, et al.. (2015). Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. 70(11). 696–697. 5 indexed citations

17.

Frankel, Paul, Timothy W. Synold, Joanne Mortimer, et al.. (2014). Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. British Journal of Cancer. 111(12). 2268–2274. 14 indexed citations

18.

Hardwick, Nicola, Vincent Chung, Mihaela Cristea, Joshua D.I. Ellenhorn, & Don J. Diamond. (2014). Overcoming immunosuppression to enhance a p53MVA vaccine. OncoImmunology. 3(10). e958949–e958949. 11 indexed citations

19.

Ettinger, David S., Mark Agulnik, Justin Cates, et al.. (2011). Occult Primary. Journal of the National Comprehensive Cancer Network. 9(12). 1358–1395. 35 indexed citations

20.

Sun, Virginia, Tami Borneman, Marianna Koczywas, et al.. (2011). Quality of life and barriers to symptom management in colon cancer. European Journal of Oncology Nursing. 16(3). 276–280. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact